Spiperone, also known as spiroperidol and sold under the brand name Spiropitan ((JP)) is a typical antipsychotic of the butyrophenone family related to haloperidol. It is approved for clinical use in Japan as a treatment for schizophrenia.
Pharmacology Pharmacodynamics + Spiperone at targets Receptor Ki (nM) Notes 5-HT1A 17.3 5-HT1B 995 5-HT1D 2397 5-HT1E 5051 5-HT1F 3.98 5-HT2A 1.17 5-HT2B 0.8–1114.2 0.8 is bovine 5-HT2C 922.9 5-HT3 >10000 Rat/other 5-HT5A 2512 Mouse 5-HT6 1590 Rat 5-HT7 109.8 α1A 20.4 α1B 3.09 α1D 8.32 D1 398.5 D2 0.16 D3 0.34 D4 1.39 D5 4500 H1 272 σ 353
Spiperone interacts with various monoamine receptors.
Additionally, spiperone was identified by compound screening to be an activator of Ca2+ activated Cl− channels (CaCCs), thus a potential target for therapy of cystic fibrosis.
Chemistry Derivatives N-Methylspiperone (NMSP) is a derivative of spiperone that is used to study the dopamine and serotonin neurotransmitter system. Labeled with the radioisotope carbon-11, it can be used for positron emission tomography.
See also Spirodecanone
References